Novartis Ag (NVS) Invested Capital (2015 - 2025)
Novartis Ag recorded quarterly Invested Capital of $46.4 billion in Q4 2025, up 3.99% quarter-over-quarter from $44.6 billion in Q4 2024, and up 3.99% year-over-year from $44.6 billion in Q4 2024.
Novartis Ag's Invested Capital history runs 11 years deep, the most recent figure standing at $46.4 billion for Q4 2025.
- In Q4 2025, Invested Capital rose 3.99% year-over-year to $46.4 billion; the TTM figure through Dec 2025 stood at $46.4 billion (up 3.99% YoY), while the FY2025 annual figure was $46.4 billion, up 3.99% from the prior year.
- Invested Capital came in at $46.4 billion for Q4 2025 at Novartis Ag, up from $44.6 billion in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $90.7 billion in Q4 2022 to a low of $44.6 billion in Q4 2024.
- A 5-year average of $59.8 billion and a median of $47.4 billion in 2023 frame the typical range for Invested Capital.
- Across the five-year window, Invested Capital soared 10355.86% in 2021 and plunged 47.76% in 2023, its largest moves.
- Novartis Ag's Invested Capital stood at $69.6 billion in 2021, then soared by 30.23% to $90.7 billion in 2022, then slumped by 47.76% to $47.4 billion in 2023, then decreased by 5.75% to $44.6 billion in 2024, then rose by 3.99% to $46.4 billion in 2025.
- According to Business Quant data, Invested Capital over the past three periods registered $46.4 billion, $44.6 billion, and $47.4 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 72.79 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 98.65 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -6.66 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 48.32 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 66.51 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 45.69 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 90.96 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 64.21 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 71.36 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46.43 Bn |
| Dec 31, 2024 | 44.65 Bn |
| Dec 31, 2023 | 47.37 Bn |
| Dec 31, 2022 | 90.69 Bn |
| Dec 31, 2021 | 69.64 Bn |
| Dec 31, 2020 | 666.00 Mn |
| Dec 31, 2019 | -3.41 Bn |
| Dec 31, 2018 | 38.84 Bn |
| Dec 31, 2017 | 34.68 Bn |
| Sep 30, 2017 | -80.00 Mn |
| Jun 30, 2017 | -105.00 Mn |
| Mar 31, 2017 | -88.00 Mn |
| Dec 31, 2016 | 74.76 Bn |
| Sep 30, 2016 | -155.00 Mn |
| Jun 30, 2016 | -210.00 Bn |
| Mar 31, 2016 | -289.00 Bn |
| Dec 31, 2015 | 76.81 Bn |
| Sep 30, 2015 | -278.00 Bn |